Literature DB >> 3020096

Growth fractions in breast cancers determined in situ with monoclonal antibody Ki-67.

J Gerdes, R J Lelle, H Pickartz, W Heidenreich, R Schwarting, L Kurtsiefer, G Stauch, H Stein.   

Abstract

The growth fractions of 160 mammary carcinomas and 30 benign mammary lesions were determined in situ by immunostaining with the monoclonal antibody Ki-67. Benign lesions had a mean value of 3% Ki-67 positive cells, whereas the mean value of mammary carcinomas was 16.6%. A comparison of the mean values of Ki-67 positive cells with the histological grade of the tumours showed a correlation between these two variables--that is, histological grade 1 showed 9%, grade 2 16%, and grade 3 26% proliferating cells. Considering the individual Ki-67 values in the different histological grades, it was evident that there was considerable scatter in the number of proliferating cells, so that the proliferation rates of grades 1, 2, and 3 overlapped each other. This indicates a dissociation between histological grade of malignancy and size of the growth fraction in most breast cancers. Follow up studies are needed to establish which of the two variables--that is, morphological degree of malignancy, or the proportion of Ki-67 positive cells--correlates better with response to treatment and survival in individual cases.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3020096      PMCID: PMC500196          DOI: 10.1136/jcp.39.9.977

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  15 in total

Review 1.  Proliferation-dependent cytotoxicity of anticancer agents: a review.

Authors:  F Valeriote; L van Putten
Journal:  Cancer Res       Date:  1975-10       Impact factor: 12.701

2.  Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67.

Authors:  J Gerdes; H Lemke; H Baisch; H H Wacker; U Schwab; H Stein
Journal:  J Immunol       Date:  1984-10       Impact factor: 5.422

3.  Growth fractions in malignant non-Hodgkin's lymphomas (NHL) as determined in situ with the monoclonal antibody Ki-67.

Authors:  J Gerdes; F Dallenbach; K Lennert; H Lemke; H Stein
Journal:  Hematol Oncol       Date:  1984 Oct-Dec       Impact factor: 5.271

4.  Prognostic factors in cancer of the female breast. II. Reproducibility of histopathologic classification.

Authors:  S J Cutler; M M Black; G H Friedell; R A Vidone; I S Goldenberg
Journal:  Cancer       Date:  1966-01       Impact factor: 6.860

5.  Rapid growth rate in breast cancer: a confounding variable in adjuvant-chemotherapy trials.

Authors:  M E Charlson; A R Feinstein
Journal:  Lancet       Date:  1982-06-12       Impact factor: 79.321

6.  Relationships of S-phase fraction of breast carcinoma in relapse to duration of remission, estrogen receptor content, therapeutic responsiveness, and duration of survival.

Authors:  J S Meyer; J Y Lee
Journal:  Cancer Res       Date:  1980-06       Impact factor: 12.701

7.  Analysis of reproducibility of subjective grading systems for breast carcinoma.

Authors:  B Stenkvist; S Westman-Naeser; J Vegelius; J Holmquist; B Nordin; E Bengtsson; O Eriksson
Journal:  J Clin Pathol       Date:  1979-10       Impact factor: 3.411

8.  Advanced stage and early relapse of breast carcinomas associated with high thymidine labeling indices.

Authors:  J S Meyer; B Hixon
Journal:  Cancer Res       Date:  1979-10       Impact factor: 12.701

9.  Identification of Hodgkin and Sternberg-reed cells as a unique cell type derived from a newly-detected small-cell population.

Authors:  H Stein; J Gerdes; U Schwab; H Lemke; D Y Mason; A Ziegler; W Schienle; V Diehl
Journal:  Int J Cancer       Date:  1982-10-15       Impact factor: 7.396

10.  Kinetic parameters and the course of the disease in breast cancer.

Authors:  M Tubiana; M J Pejovic; A Renaud; G Contesso; N Chavaudra; J Gioanni; E P Malaise
Journal:  Cancer       Date:  1981-03-01       Impact factor: 6.860

View more
  56 in total

Review 1.  Molecular basis for therapy resistance.

Authors:  Per E Lønning
Journal:  Mol Oncol       Date:  2010-04-24       Impact factor: 6.603

2.  Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67.

Authors:  J Gerdes; L Li; C Schlueter; M Duchrow; C Wohlenberg; C Gerlach; I Stahmer; S Kloth; E Brandt; H D Flad
Journal:  Am J Pathol       Date:  1991-04       Impact factor: 4.307

Review 3.  How malignant is malignant? A brief review of the microscopic assessment of human neoplasms, and the prediction of whether they will metastasize and kill.

Authors:  I Carr; N Pettigrew
Journal:  Clin Exp Metastasis       Date:  1991 Mar-Apr       Impact factor: 5.150

4.  Biological grading of breast cancer using antibodies to proliferating cells and other markers.

Authors:  S S Bacus; R Goldschmidt; D Chin; G Moran; D Weinberg; J W Bacus
Journal:  Am J Pathol       Date:  1989-11       Impact factor: 4.307

5.  Assessment of proliferation of squamous, Barrett's and gastric mucosa in patients with columnar lined Barrett's oesophagus.

Authors:  S Y Iftikhar; R J Steele; S Watson; P D James; K Dilks; J D Hardcastle
Journal:  Gut       Date:  1992-06       Impact factor: 23.059

6.  Characterisation of normal peripheral blood cells in cycle identified by monoclonal antibody Ki-67.

Authors:  I Cordone; E Matutes; D Catovsky
Journal:  J Clin Pathol       Date:  1992-03       Impact factor: 3.411

7.  Proliferation markers Ki-67 and p105 in soft-tissue lesions. Correlation with DNA flow cytometric characteristics.

Authors:  S A Swanson; J J Brooks
Journal:  Am J Pathol       Date:  1990-12       Impact factor: 4.307

8.  Nucleolar grading of breast cancer. Comparative studies on frequency and localization of nucleoli and histology, stage, hormonal receptor status and lectin histochemistry.

Authors:  B Helpap
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1989

9.  Ki-67 staining in histological subtypes of breast carcinoma and fine needle aspiration smears.

Authors:  V Kuenen-Boumeester; T H Van Der Kwast; H A Van Laarhoven; S C Henzen-Logmans
Journal:  J Clin Pathol       Date:  1991-03       Impact factor: 3.411

10.  Immunohistochemical analysis of gastrointestinal carcinoids.

Authors:  H Hayashi; M Nakagawa; S Kitagawa; T Yamada; K Ishida; H Kurumaya
Journal:  Gastroenterol Jpn       Date:  1993-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.